Welcome to our dedicated page for Krystal Biotech news (Ticker: KRYS), a resource for investors and traders seeking the latest updates and insights on Krystal Biotech stock.
Krystal Biotech, Inc. (KRYS) is a leader in redosable gene therapies targeting rare dermatological conditions and respiratory diseases through its proprietary HSV-1 delivery platform. This page aggregates official press releases, clinical trial updates, and regulatory developments directly from the company.
Investors and researchers can monitor progress across four key areas: dermatology (including VYJUVEK commercialization), oncology (KB707 cytokine therapy), respiratory (inhaled genetic medicines), and aesthetic medicine through subsidiary Jeune Aesthetics. All content is sourced from verified corporate communications.
Bookmark this page for real-time updates on FDA submissions, partnership announcements, and financial results. Our curation ensures you never miss critical developments in KRYS's mission to transform genetic medicine delivery.
On April 23, 2023, at the ARVO Annual Meeting, Krystal Biotech (NASDAQ: KRYS) presented promising data on the compassionate use of its gene therapy B-VEC for treating dystrophic epidermolysis bullosa (DEB) patients with ocular complications. The therapy, administered to a patient with recurrent cicatrizing conjunctivitis, showed significant results: full corneal re-epithelization within three months and improved visual acuity from hand motion to 20/40 at seven months. No drug-related adverse events were reported, underscoring the safety of B-VEC. With ocular complications affecting over half of DEB patients, this innovative treatment may address an urgent need in this underserved population, prompting the company to engage with regulatory authorities for further exploration of B-VEC’s applications.
FAQ
What is the current stock price of Krystal Biotech (KRYS)?
What is the market cap of Krystal Biotech (KRYS)?
